Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study
Min Seo Kim
(1, 2)
,
Se Yong Jung
(3)
,
Seung Won Lee
(4)
,
Han Li
(5)
,
Ai Koyanagi
(6, 7)
,
Andreas Kronbichler
(8)
,
Elena Dragioti
(9)
,
Kalthoum Tizaoui
(10)
,
Paul Wasuwanich
(5)
,
Sung Hwi Hong
(3)
,
Ramy Abou Ghayda
(11)
,
Hae Won Yoo
(12)
,
Hanna Kim
(13)
,
Louis Jacob
(7, 14)
,
Joe-Elie Salem
(15, 16, 17, 18)
,
Karel Kostev
(19)
,
Youn Ho Shin
(20)
,
So Young Kim
(20)
,
Gabriele Gamerith
(8)
,
Dong Keon Yon
(21)
,
Jae Il Shin
(3)
,
Lee Smith
(22)
1
SKKU -
Sungkyunkwan University [Suwon]
2 Korea University [Seoul]
3 Yonsei University
4 Sejong University
5 The University of Florida College of Medicine
6 ISCIII - Instituto de Salud Carlos III [Madrid]
7 UB - Universitat de Barcelona
8 IMU - Innsbruck Medical University = Medizinische Universität Innsbruck
9 LIU - Linköping University
10 University of Tunis El Manar
11 Case Western Reserve University [Cleveland]
12 Soonchunhyang University [Asan]
13 EWHA - EWHA Womans University
14 UVSQ - Université de Versailles Saint-Quentin-en-Yvelines
15 CIC Paris-Est - Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière]
16 CHU Pitié-Salpêtrière [AP-HP]
17 Institut Galilée
18 ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
19 Philipps Universität Marburg = Philipps University of Marburg
20 CHA University [Gyeonggi-do, South Korea]
21 SNU - Seoul National University [Seoul]
22 ARU - Anglia Ruskin University
2 Korea University [Seoul]
3 Yonsei University
4 Sejong University
5 The University of Florida College of Medicine
6 ISCIII - Instituto de Salud Carlos III [Madrid]
7 UB - Universitat de Barcelona
8 IMU - Innsbruck Medical University = Medizinische Universität Innsbruck
9 LIU - Linköping University
10 University of Tunis El Manar
11 Case Western Reserve University [Cleveland]
12 Soonchunhyang University [Asan]
13 EWHA - EWHA Womans University
14 UVSQ - Université de Versailles Saint-Quentin-en-Yvelines
15 CIC Paris-Est - Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière]
16 CHU Pitié-Salpêtrière [AP-HP]
17 Institut Galilée
18 ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
19 Philipps Universität Marburg = Philipps University of Marburg
20 CHA University [Gyeonggi-do, South Korea]
21 SNU - Seoul National University [Seoul]
22 ARU - Anglia Ruskin University
Joe-Elie Salem
- Fonction : Auteur
- PersonId : 777251
- IdHAL : joe-elie-salem
- ORCID : 0000-0002-0331-3307
- IdRef : 160947227
Résumé
Remdesivir has demonstrated clinical benefits in randomized placebo-controlled trials (RCTs) in patients with coronavirus disease 2019 (COVID-19)1-4 and was first approved for COVID-19 patients.5 However, whether remdesivir causes gastrointestinal adverse drug reaction (GI-ADRs) including hepatotoxicity is less clear.1-4,6 Therefore, we aimed to detect a diverse spectrum of GI-ADRs associated with remdesivir using VigiBase, the World Health Organization's international pharmacovigilance database of individual case safety reports.